PE20191654A1 - Composicion mejorada de lansoprazol y simeticona y proceso para prepararla - Google Patents

Composicion mejorada de lansoprazol y simeticona y proceso para prepararla

Info

Publication number
PE20191654A1
PE20191654A1 PE2019001165A PE2019001165A PE20191654A1 PE 20191654 A1 PE20191654 A1 PE 20191654A1 PE 2019001165 A PE2019001165 A PE 2019001165A PE 2019001165 A PE2019001165 A PE 2019001165A PE 20191654 A1 PE20191654 A1 PE 20191654A1
Authority
PE
Peru
Prior art keywords
microgranules
lansoprazole
symeticone
prepare
improved composition
Prior art date
Application number
PE2019001165A
Other languages
English (en)
Inventor
Esteban Alejandro Fiore
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of PE20191654A1 publication Critical patent/PE20191654A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Referido a una composicion farmaceutica de administracion oral que comprende entre 120 mg y 200 mg de simeticona y entre 15 mg y 60 mg de lansoprazol o Dexlansoprazol, caracterizada porque la simeticona se encuentra bajo la forma de microgranulos de elevada concentracion, siendo dicha concentracion mayor o igual a 500 mg/g, y lanzoprazol en microgranulos de liberacion enterica; en donde los microgranulos estan formados por esferas de azucar, dioxido de silicio coloidal, carbonato de magnesio y opcionalmente otros excipientes farmaceuticos. Esta composicion farmaceutica esta formada por una capsula dura. Tambien se refiere a un proceso para preparar microgranulos.
PE2019001165A 2016-12-14 2017-12-13 Composicion mejorada de lansoprazol y simeticona y proceso para prepararla PE20191654A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2016016587A MX2016016587A (es) 2016-12-14 2016-12-14 Composicion mejorada de lansoprazol y simeticona y procesos para prepararla.
PCT/IB2017/057904 WO2018109693A1 (es) 2016-12-14 2017-12-13 Composición mejorada de lansoprazol y simeticona y proceso para prepararla

Publications (1)

Publication Number Publication Date
PE20191654A1 true PE20191654A1 (es) 2019-11-07

Family

ID=62558163

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001165A PE20191654A1 (es) 2016-12-14 2017-12-13 Composicion mejorada de lansoprazol y simeticona y proceso para prepararla

Country Status (9)

Country Link
AR (1) AR110183A1 (es)
BR (1) BR112019011966A2 (es)
CL (1) CL2019001462A1 (es)
CO (1) CO2019006693A2 (es)
CR (1) CR20190290A (es)
DO (1) DOP2019000145A (es)
MX (1) MX2016016587A (es)
PE (1) PE20191654A1 (es)
WO (1) WO2018109693A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073384A (en) * 1989-10-19 1991-12-17 Valentine Enterprises, Inc. Maltodextrin/defoaming composition combinate
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
WO2008056200A1 (en) * 2006-11-10 2008-05-15 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of simethicone
AU2012327176B2 (en) * 2011-12-14 2015-08-13 Disphar International B.V. Simethicone formulation

Also Published As

Publication number Publication date
CO2019006693A2 (es) 2019-07-10
CL2019001462A1 (es) 2019-08-23
AR110183A1 (es) 2019-03-06
MX2016016587A (es) 2018-06-13
BR112019011966A2 (pt) 2019-11-05
CR20190290A (es) 2019-11-18
WO2018109693A1 (es) 2018-06-21
DOP2019000145A (es) 2019-08-15

Similar Documents

Publication Publication Date Title
CL2018003700A1 (es) Terapias de combinación.
MX2018004328A (es) Composiciones farmaceuticas estabilizantes de camptotecina.
RU2015138708A (ru) Фармацевтические композиции для лечения от helicobacter pylori
CU24486B1 (es) Dispersión sólida amorfa que comprende taxano, tabletas comprendiendo la misma y método para prepararla
PE20181521A1 (es) Composicion farmaceutica que comprende un potente inhibidor de urat1
JP2016508516A5 (es)
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
MX2016014771A (es) Forma de dosificacion oralmente desintegrante para administracion de avanafil, y metodos de fabricacion y uso asociados.
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
JP2014210824A5 (es)
MX2020011474A (es) Nuevo tratamiento de enfermedades pulmonares intersticiales.
WO2013175494A3 (en) Controlled release pharmaceutical formulations of direct thrombin inhibitors
PE20191654A1 (es) Composicion mejorada de lansoprazol y simeticona y proceso para prepararla
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
PH12018502524A1 (en) Physiologically balanced injectable formulations of fosnetupitant
ECSP19044926A (es) Composición mejorada de lansoprazol y simeticona y proceso para prepararla
TR201722323A2 (tr) Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari
TR201722186A2 (tr) Dabi̇gatranin farmasöti̇k kompozi̇syonlari
EA201691763A1 (ru) Стабильная быстрорастворимая лекарственная форма, содержащая амоксициллин и клавулановую кислоту
EA201991288A1 (ru) Фармацевтические композиции на основе дабигатрана
CO2019008347A2 (es) Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla
WO2019151966A3 (en) Pharmaceutical tablet compositions of dabigatran
PE20151431A1 (es) Formulaciones de lorazepam de liberacion controlada
Wood Dabigatran etexilate/tartaric acid